Skip to main content

Neurocrine Biosciences Inc

Exchange: NASDAQSector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic

Biosciences, Inc. Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, endocrine, psychiatric and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders because you deserve brave science.

Did you know?

Earnings per share grew at a 50.0% CAGR.

Current Price

$131.78

+0.08%

GoodMoat Value

$213.39

61.9% undervalued
Profile
Valuation (TTM)
Market Cap$13.14B
P/E27.45
EV
P/B4.04
Shares Out99.71M
P/Sales4.59
Revenue$2.86B
EV/EBITDA15.84

Neurocrine Biosciences Inc (NBIX) Stock News

NBIX Stock News & Headlines

Latest stock news and headlines for Neurocrine Biosciences Inc (NBIX). Stay informed on earnings reports, analyst upgrades and downgrades, market-moving events, and company announcements.

Current stock price: $131.78. Market cap: $13.14B. Sector: Healthcare. Industry: Drug Manufacturers - Specialty & Generic. This page aggregates the latest news articles relevant to NBIX from financial news sources, helping investors stay current on events that may impact Neurocrine Biosciences Inc's stock price.

News catalysts can drive significant short-term price movement. Earnings surprises, management changes, product launches, regulatory decisions, and analyst coverage changes all create opportunities and risks. Combine news monitoring with GoodMoat's fundamental analysis, quality scores, and valuation tools for a complete research workflow on Neurocrine Biosciences Inc (NBIX).